Evonik’s 9 November EuroTier announcement outlined two different stages of development in its Specialty Nutrition portfolio. Lypron was described as a recently launched rumen-protected lysine for dairy cows, while ZyneXtra was scheduled for preview ahead of a planned launch in the first quarter of 2027.
The announcement related to EuroTier in Hanover on 10–13 November. It presented Lypron in the context of amino-acid balancing and positioned ZyneXtra around feed analytics, nutritional expertise and targeted enzyme solutions for variable non-starch polysaccharides in raw materials.
These are the supplier’s descriptions of intended applications. The preview timetable does not establish universal availability, local registration or independently verified results at a particular farm.
Match the question to the application
The distinction matters when requesting technical information. A protected amino-acid product for dairy cattle and an enzyme-related programme require different evidence, formulation assumptions and evaluation methods.
Buyers can first establish whether they are discussing an available product, a demonstration or a future commercial offer. The next questions concern the relevant species, raw-material matrix and conditions behind any claimed benefit.
Evonik also promoted methionine comparisons at the event. Such supplier comparisons should be examined against their study conditions rather than converted into a universal substitution instruction. This report does not prescribe inclusion rates or infer that one product can be exchanged for another without a formulation assessment.
Dairy cattle in a barn; not an Evonik product trial or customer installation.
Further reading
Researched and written with AI assistance; references are listed for verification.



